Cardiomyopathy Overview
Cardiomyopathy Overview
Cardiomyopathy is a disease of the heart muscle itself — not of the arteries that feed it, not of the valves that seal it, not of the sac around it. The muscle becomes thick, or dilated and weak, or stiff and unwilling to fill, and everything the heart does is affected from the inside. This guide sets out the main types and the infiltrative conditions that imitate them, how each one announces itself or stays silent, what imaging, rhythm assessment and genetic testing can now establish, and the reasoning behind medication, devices, septal reduction and transplant assessment.
-
24/7
Emergency cardiac intervention cover at both flagship hospitals
-
170
Specialised cardiovascular beds across the two flagship hospitals
-
5
National certifications at the Foshan hospital, the first in its city to hold all five
-
124+
Countries and regions our international patients come from
What cardiomyopathy is — a disease of the muscle itself
The heart is a pump built from muscle, and four different structures can go wrong in ways that all produce the same complaint. The arteries that feed the muscle can narrow. The valves that seal its chambers can leak or stiffen. The sac that surrounds it can fill with fluid. And the muscle itself can be abnormal. Cardiomyopathy is the fourth of these. The word says exactly what it means — cardio, the heart; myo, muscle; pathy, disease — and it covers a group of conditions in which the heart muscle is structurally or functionally abnormal for reasons that the arteries, the valves and the loading conditions do not explain.
That qualification is the whole point, and it is why the label is often delayed. A heart can be dilated and weak because three coronary arteries are blocked, or because a gene that builds the muscle's contractile proteins is altered — and the treatment, and what the answer means for the family, are different. Cardiomyopathy is the name that is used once the arteries, the valves and the blood pressure have been accounted for and the muscle is still the problem. It does not require the coronary arteries to be perfectly clean: a narrowed artery and a cardiomyopathy can coexist, and often do. It requires only that they do not explain what the muscle is doing.
Mechanically the muscle can fail in three directions, and most of the vocabulary of cardiomyopathy comes from them. It can become thick — the walls crowd inwards and the chamber holds less, which is hypertrophic cardiomyopathy. It can become dilated and weak — the chamber stretches, the walls thin, and the pump empties incompletely, which is dilated cardiomyopathy. Or it can become stiff — the walls are not thick enough to account for how badly the chamber refuses to relax and fill, which is restrictive cardiomyopathy. A fourth group does not sit neatly in any of the three: conditions in which a substance is deposited inside the muscle, or in which the muscle's electrical behaviour fails before its pumping does.
One boundary belongs at the top of this guide, because patients arrive carrying the confusion. Cardiomyopathy is not heart failure, and it is not coronary disease. Heart failure is a syndrome — the collection of symptoms that appears when the pump cannot meet what the body is asking of it, whatever the cause — and its day-to-day management, from diuretics to fluid balance to rehabilitation, is set out in our guide to heart failure. Cardiomyopathy is a disease of the muscle that very often produces that syndrome. The distinction is practical rather than academic: this guide is about what is wrong with the muscle, what caused it, and what therefore has to happen for the patient and for the people who share the patient's genes.
The main types, and the conditions that imitate them
Cardiomyopathies are sorted by what the muscle looks like and by what it does — a classification that sounds like anatomy but is really a statement about mechanism and treatment. Four groups cover almost everything a patient will be told they have, and a fifth exists to catch the conditions that imitate them.
| Type | What the muscle is doing | What it means for treatment |
|---|---|---|
| Dilated cardiomyopathy (DCM) | The chamber enlarges and the walls thin; contraction is weak and the pump empties incompletely, so pressure builds up behind it | The foundation is the medication that unloads the heart and blocks the hormonal drive that keeps reshaping it; devices and advanced options are considered when the pump stays weak |
| Hypertrophic cardiomyopathy (HCM) | The muscle thickens, most often the septum, and the thickening may narrow the outflow tract (obstructive) or leave it open (non-obstructive) | Medicines that slow the heart and reduce contractility come first; where obstruction persists and symptoms continue, the septum itself is treated — surgically or through a catheter |
| Restrictive cardiomyopathy (RCM) | The walls are stiff and the chamber refuses to fill at ordinary pressures; contraction may measure normally while filling fails | Treatment is aimed at the cause and at congestion, and it is given carefully: a stiff heart depends on the very filling pressure that ordinary diuretics remove |
| Arrhythmogenic cardiomyopathy (ARVC) | Muscle in the right, and sometimes the left, ventricle is replaced by scar and fat, and the heart becomes electrically unstable before it becomes weak | The priority is protection from rhythm events, restriction of the exercise types that provoke them, and — where risk is high — a defibrillator |
| Infiltrative and storage disease | Something else is inside the muscle: misfolded protein in amyloidosis, inflammatory cells in sarcoidosis, iron in haemochromatosis, a missing enzyme in Fabry disease | These are treated as their own diseases, which is exactly why they have to be named — the therapy is directed at the deposit, not at the pump |
Two things are worth saying about this list. The first is that the groups overlap and evolve: a heart can move from one column to another over the years, and a patient can carry features of two at once. The second is that the distinctions are not academic. A beta-blocker improves symptoms in obstructive HCM and is also standard treatment in DCM, but for different reasons and with a different dose logic. Immunosuppression is central to cardiac sarcoidosis and irrelevant to a variant in a contractile protein. And for amyloidosis, naming the condition is the single most consequential step, because the therapy that follows is aimed at the protein rather than at the heart. The rest of this guide follows the same thread: what started the disease comes first, then how the type is established, then what is done about it.
How severity is read: four axes, not one number
Cardiomyopathy does not come with stage numbers, and patients who have been through cancer care sometimes find that silence unsettling: there is no equivalent of a stage II or a grade 3 to hold on to. Severity is read instead across four axes at once, plus a fifth that applies only to obstructive disease — and they are deliberately kept apart, because the axis that decides a medicine is not the axis that decides a defibrillator.
| Axis | What is being read | What it changes |
|---|---|---|
| Structure | How thick the walls are, how large the chamber is, which segments move abnormally, and how much scar the MRI shows | Names the type, and the amount of scar feeds directly into the assessment of rhythm risk |
| Pump function | The ejection fraction and, just as importantly, how the heart behaves under load — exercise capacity and the pressures inside the chambers | Sets the medication strategy and the threshold at which devices and advanced options are discussed |
| Symptoms | The functional class: how much breathlessness or fatigue ordinary activity produces, measured against the patient's own baseline rather than against a textbook | Sets how urgent treatment is, and it is the yardstick against which any change is judged |
| Rhythm risk | Documented arrhythmia, fainting that the assessment attributes to the heart, the family history, the wall thickness and the scar — assembled into a risk estimate | Decides whether a defibrillator is discussed at all, and it is read independently of how well the pump is doing |
| Obstruction (hypertrophic disease only) | The pressure gradient across the outflow tract, at rest and with provocation | Decides whether the obstruction can be managed with medicine or whether the septum itself has to be dealt with |
Three consequences follow, and they are the reason the axes are kept apart. A normal ejection fraction is not reassurance. In hypertrophic and restrictive disease the pump can measure normally while the heart is already failing at its job, because the problem is filling rather than squeezing — which is why the assessment of these patients leans on imaging, on exercise capacity and on the electrical picture rather than on that single number. The risk of a rhythm event is not the severity of the pump failure. Some of the patients at the highest risk of a dangerous arrhythmia have hearts that look only modestly affected, while some of the patients with the weakest pumps are not the ones whose rhythm fails. Severity is a moving picture, not a snapshot. One set of measurements taken on one afternoon can mislead in both directions — a good day underestimates, a decompensated week overestimates — and the useful comparison is against the same patient a year ago.
This is also why a report that says only "cardiomyopathy" has not answered the question. What a patient needs to be able to say is what the muscle is doing, what the numbers are and what the risk is — three answers that the work-up described on the diagnosis page of this guide is designed to produce, and that any second opinion should be able to restate.
How the diagnosis is built: three questions in order
The pathway in cardiomyopathy is easier to follow if it is treated as three questions asked in a deliberate order, rather than as a list of tests to be worked through. Each question has a different purpose, and the answer to the earlier one changes what the later one is looking for.
Echocardiography names the pattern; cardiac MRI separates the look-alikes by describing the tissue itself — whether thickening comes from training or from disease, whether there is scar, whether something has been deposited. The answer decides which of the groups the patient belongs to, and that in turn decides what the rest of the work-up has to exclude.
The pump and the rhythm are assessed together here: the ejection fraction and how the heart behaves during exercise, alongside the ECG, ambulatory monitoring and the features that predict a dangerous arrhythmia. The two halves are kept in one step on purpose, because they are read together when a medicine or a device is chosen.
The search runs from what is treatable to what is inherited: iron studies, protein electrophoresis and free light chains where infiltration is possible; genetic testing where a result would change what relatives are offered; and always the family history. This question is asked last and matters longest, because unlike the first two it does not change only the patient's plan.
Two consequences follow from taking the questions in this order. The first is that the work-up can stop early when the answer is already sufficient: a young patient with an obviously obstructed septum and a clear family history may need very little beyond imaging, and a patient whose MRI has already identified the disease does not need the tests that existed only to distinguish it. The second is that the work-up cannot stop at a label. It is complete when the record answers what the muscle is doing, what the risk is, what caused it, and what should happen next — for the patient and for relatives. What each test actually contributes, and where each one stops being useful, is set out in detail on the diagnosis page.
A word about the family, because it is the part of the work-up that patients least expect. In many cardiomyopathies the cause is inherited, and the first relative to be diagnosed is often the one whose investigation uncovers a risk that several other family members share. Screening relatives is not an add-on to the work-up; in the inherited forms it is the part of the result that reaches the most people. Who should be tested, with what, and at what interval, is described on the prevention page, together with what to do with a normal result and with a gene variant.
One practical note before the tests themselves: the sensation that brings most patients to this pathway is not dramatic. It is breathlessness that has crept in over a season, or a fainting episode during sport, or a murmur heard at a routine examination. Which symptoms actually point to the muscle, and which ones are emergencies, is the subject of the next page.
Why patients travel to China for cardiomyopathy care
Cardiomyopathy is a disease of decisions taken over years: which type this is, which medicine to use, whether a device is warranted, whether the septum has to be reduced, whether the family should be tested. Those decisions rest on imaging and on the electrical assessment, both of which travel well, and on a team that can hold every thread at once — cardiology, imaging, electrophysiology, cardiac surgery and genetics in one conversation rather than across separate referrals.
Our cardiovascular service spans two flagship hospitals — Fosun Hospital Foshan and Fosun Hospital Guangzhou — with nearly 170 specialised cardiovascular beds, modern coronary care units and advanced catheterisation laboratories. Emergency cover, including cardiac intervention, runs around the clock at both. The Foshan hospital holds national certifications in five areas — chest pain, atrial fibrillation, heart failure, cardiac rehabilitation and hypertension — the first hospital in its city to hold all five, and the Guangzhou hospital obtained national chest pain centre certification in 2025. Because the disease work is delivered inside one cardiovascular service, device implantation, septal reduction and cardiac surgery with on-site surgical backup are arranged by the same team that makes the diagnosis, rather than by a new set of referrals.
For a visiting patient, records reviewed by a cardiology team receive a written opinion within about 48 hours of complete records arriving — and for cardiomyopathy the records that matter are the images themselves: the echocardiogram, the MRI disc, the Holter recording, and the family history written down rather than remembered. Complete treatment in China typically runs at 30–50% of comparable care in Europe or the United States; we work with more than 30 commercial insurers for direct billing, and our international patients have come from 124 countries and regions. Because much of cardiomyopathy care is surveillance rather than a single procedure, the follow-up plan is agreed in writing before the patient flies home, and the reviews that can be done remotely are named from the start.